You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK3

Showing 1 - 25 of 546
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cicatricial Alopecia Trial in New York (PF-06651600)

Not yet recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Sep 19, 2022

Healthy Trial in New Haven (Ritlecitinib 50 mg, Ritlecitinib 200 mg)

Completed
  • Healthy
  • Ritlecitinib 50 mg
  • Ritlecitinib 200 mg
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Feb 4, 2022

Polycythemia Vera Trial (Givinostat Hydrochloride, Hydroxy Urea)

Not yet recruiting
  • Polycythemia Vera
  • Givinostat Hydrochloride
  • Hydroxy Urea
  • (no location specified)
Oct 19, 2023

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, other, radiation)

Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma Trial in Seattle

Recruiting
  • Metastatic Leiomyosarcoma
  • +17 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 13, 2022

Myeloproliferative Tumor, Splanchnic Vein Thrombosis, JAK2 V617 Trial in London (Drugs, procedures)

Enrolling by invitation
  • Myeloproliferative Neoplasm
  • +2 more
  • Drugs, procedures
  • London, United Kingdom
    Royal Free London Hospital
Jul 29, 2021

Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression

Completed
  • Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
  • JAK expression
  • Mansoura, Egypt
    Mansoura University Hospital
Dec 9, 2020

Vitiligo, JAK Inhibitor Trial in Canada, United States (Ruxolitinib 1.5% cream, NB-UVB phototherapy)

Recruiting
  • Vitiligo
  • JAK Inhibitor
  • Ruxolitinib 1.5% cream
  • NB-UVB phototherapy
  • Fountain Valley, California
  • +13 more
Jul 6, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)

Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jun 21, 2022

Leukemia Trial in Canada, Puerto Rico, United States (Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Cyclophosphamide)

Recruiting
  • Leukemia
  • Birmingham, Alabama
  • +109 more
Aug 11, 2022

Chronic Myeloproliferative Tumors Trial in Germany, Italy, United Kingdom (givinostat)

Active, not recruiting
  • Chronic Myeloproliferative Neoplasms
  • Berlin, Germany
  • +14 more
Jun 14, 2021

COVID19, COVID-19, COVID Trial in United States (Pacritinib, Placebo)

Terminated
  • COVID19
  • +2 more
  • Orange, California
  • +20 more
Sep 23, 2021

COVID-19 Trial in Chengdu (VV116+SOC, SOC)

Recruiting
  • COVID-19
  • Chengdu, Sichuan, China
    Chengdu Zenitar Biomedical Technology Co., Ltd
Feb 3, 2023

Vitiligo, Generalized Trial (Baricitinib)

Not yet recruiting
  • Vitiligo, Generalized
  • (no location specified)
Jul 7, 2023

Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)

Recruiting
  • Alopecia Areata
  • Janus Kinase 1 and 2
  • Sohag, Egypt
    Sohag University hospitals
May 12, 2023

COVID-19 Trial in Russian Federation, United States (Placebo, Ruxolitinib)

Terminated
Has Results
  • COVID-19
  • Scottsdale, Arizona
  • +35 more
Jan 14, 2022

Genetic Basis of Primary Immunodeficiencies

Terminated
  • Immunologic Deficiency Syndrome
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    May 26, 2021

    Primary Immunodeficiency Diseases

    Active, not recruiting
    • Wiskott- Aldrich Syndrome
    • ADA Deficient SCID
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 13, 2023

      Healthy Volunteers, Adult, Pharmacokinetics Trial in Brussels (Ritlecitinib)

      Not yet recruiting
      • Healthy Volunteers
      • +2 more
      • Brussels, Bruxelles-capitale, Région DE, Belgium
        Brussels Clinical Research Unit
      May 1, 2023

      Genetic Basis of Immunodeficiency

      Recruiting
      • Severe Combined Immunodeficiency
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 21, 2023

        JAK-STAT Signaling Pathway in Pyoderma Gangrenosum

        Not yet recruiting
        • Pyoderma Gangrenosum
        • +2 more
        • immunohistochemical methods
        • (no location specified)
        Mar 21, 2022

        Severe Combined Immune Deficiency (SCID) Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)

        Enrolling by invitation
        • Severe Combined Immune Deficiency (SCID)
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Aug 24, 2022

        Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis Trial in Worldwide (ACE-536, Placebo)

        Recruiting
        • Myeloproliferative Disorders
        • +4 more
        • La Jolla, California
        • +184 more
        Aug 22, 2022

        Action of Interferon in Treatment of Myeloproliferative

        Recruiting
        • Myeloproliferative Neoplasm
          • Villejuif, Ile De France, France
            Inserm U1287
          Apr 28, 2023

          Kohlmeier Degos Disease With Neurologic Involvement Trial run by the National Heart, Lung, and Blood Institute (NHLBI)

          Recruiting
          • Kohlmeier Degos Disease With Neurologic Involvement
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Aug 23, 2023